Table 1.

Patient and disease characteristics

Patients (n, %)
Age, years (median, range) 59 (23–82)Metastatic sites
Performance status Lymph nodes42 (32.3)
 0–1111 (85.4) Lung46 (35.4)
 2–317 (13.1) Bones58 (44.6)
 Unknown2 (1.5) Liver44 (33.8)
Menopausal status Skin10 (7.7)
 Premenopausal41 (31.5) CNS7 (5.4)
 Postmenopausal82 (63.1)No. of affected organs
 Unknown7 (5.4) 1–285 (65.4)
Histological grade ≥342 (32.3)
 I–II53 (40.8) Unknown3 (2.3)
 III61 (46.9)Type of first-line chemotherapy
 Unknown16 (12.3) Tax or Anthr single agents21 (16.2)
Adjuvant chemotherapy Tax-based combinations75 (57.7)
 Yes67 (51.5) Combinations without Tax or Anthr34 (26.2)
 No62 (47.7)Response to treatment
 Unknown1 (0.8) Complete response10 (7.7)
Histology subtype Partial response52 (40)
 Ductal99 (76.2) Stable disease46 (35.4)
 Lobular13 (10) Progressive disease17 (13.1)
 Mixed8 (6.2) Unknown5 (3.9)
 Unknown10 (7.7)Disease status at the end of chemotherapy
Molecular subtype Complete response12 (9.2)
 ER-positive89 (68.5) Partial response37 (28.5)
 PgR-positive83 (63.8) Stable disease44 (33.8)
 HER2-positive28 (21.5) Progressive disease32 (24.6)
 Triple-negative19 (14.6) Unknown5 (3.9)
  • NOTE: No of patients: n = 130.

  • Abbreviations: Anthr, anthracyclines; CNS, central nervous system; ER, estrogen receptor; PgR, progesterone receptor; Tax, Taxanes.